Monday, February 6, 2023
HomeOpinionAclarion’s Key Opinion Chief Program Provides Fifth Surgeon

Aclarion’s Key Opinion Chief Program Provides Fifth Surgeon

Growth of this program helps Aclarion’s dedication to steer with sturdy scientific proof and interact the payer neighborhood via key opinion chief advocacy.

Broomfield, CO, Dec. 21, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc. (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the placement of continual low again ache, introduced right now that Eric Potts M.D., Neurosurgeon at Ascension St. Vincent Hospital and member of the Board of Administrators on the Goodman Campbell Mind and Backbone in Indianapolis, IN, will advise the corporate as a key opinion chief (KOL) nationally. 

Power low again ache (cLBP) is a main reason behind opioid habit within the U.S. and the one costliest prognosis in america.  Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies essential insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods.

Dr. Potts is chair-elect of the American Affiliation of Neurological Surgeons and the Congress of Neurological Surgeons (AANS/CNS) Joint Part on the Issues of the Backbone and Peripheral Nerves. He has been a long-standing Govt Committee member of this group. Dr. Potts is captivated with modern applied sciences and equally centered on enhancing high quality outcomes. “In my scientific observe and thru societal management roles, I regularly try to search out the improvements that serve our trade and my sufferers. Nociscan represents a very disruptive innovation that addresses a serious hole in right now’s diagnostic choices,” acknowledged Dr. Potts. “Aclarion has developed a non-invasive strategy to amassing and analyzing biomarker knowledge, which is revolutionizing the way in which low again ache is known and handled.”

Aclarion is following a centered technique of constructing sturdy scientific proof and neurosurgery and backbone society help. “Dr. Potts is a pacesetter inside his space of experience and an lively participant within the Neuropoint Alliance High quality Outcomes Database. He personifies our shared dedication to innovation and scientific management,” stated Brent Ness, CEO of Aclarion. “We’re happy to welcome Dr. Potts to Aclarion’s advisory crew.”

About Aclarion, Inc.

Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific remedies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies essential insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods.  For extra data, please go to www.aclarion.com

Ahead Wanting Statements

This press launch comprises forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, comparable to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to quite a lot of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to evaluation the part titled “Threat Elements” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Change Fee on April 25, 2022 below Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.

Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com

Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular